Insights Into Patient‐Level Exposure to Actionable Pharmacogenomic Medications in Australia Using a New National Pharmacogenomic Guideline
Clinical Pharmacology & Therapeutics · 2026-01 · 119 (1) · 89-100
DOI: 10.1002/cpt.70006 ↗Kurz gefasst
Leitlinie in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 18.07.2025. Verfasst von Bella D Ianni und 3 weiteren Autor:innen. Beteiligte Einrichtung: The University of Sydney School of Pharmacy, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Pharmacogenomic Testing, Pharmacogenetics, Practice Patterns, Physicians'. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
This study assessed the use of 35 pharmacogenomic (PGx) medications listed in the Royal College of Pathologists of Australasia (RCPA) guideline, estimated the potential costs of subsidizing PGx testing in Australia, and predicted related prescribing changes. Using administrative claims data from the Pharmaceutical Benefits Scheme, accessed via the Australian Bureau of Statistics DataLab, we identified individuals who received any of the 35 medications between January 2021 and December 2023. Incident prescribing rates were calculated for children (0–17), adults (18–64), and older adults (65+). Adults (14.91%) and older adults (14.44%) had the highest rates of PGx medication use, followed by children (3.53%). Commonly prescribed medications included proton pump inhibitors, with frequent associations to genes such as CYP2C19 across all age groups. Estimated costs of PGx testing, assuming 50% and 75% population uptake, were highest for older adults: AUD$1.95 million and AUD$2.93 million, respectively. Predicted prescribing changes, based on literature‐reported phenotype frequencies by ancestry, suggested that up to 18.58% of individuals using drugs like clopidogrel or voriconazole may need alternative treatments due to poor metabolism. These findings highlight the clinical potential of integrating PGx testing into routine practice, especially for medications included in international pharmacogenomic guidelines. While implementation would entail significant upfront costs, PGx testing could enhance medication safety and effectiveness and health care cost‐efficiency. Future research should focus on scalable strategies for PGx implementation across diverse health care settings to optimize patient care globally.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The University of Sydney School of Pharmacy, Sydney, New South Wales, Australia.
- Kolling Institute, Faculty of Medicine and Health, The University of Sydney and the Northern Sydney Local Health District, Sydney, New South Wales, Australia.
- Department of Pharmacy, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
ORCID-Profile: Bella D Ianni, Chin Hang Yiu, Mohammad A Ali, Christine Y Lu
Zitieren
APA
Ianni, B. D., Yiu, C. H., Ali, M. A., & Lu, C. Y. (2026). Insights Into Patient‐Level Exposure to Actionable Pharmacogenomic Medications in Australia Using a New National Pharmacogenomic Guideline. Clinical Pharmacology & Therapeutics, 119(1), 89-100. https://doi.org/10.1002/cpt.70006
Vancouver
Ianni BD, Yiu CH, Ali MA, Lu CY. Insights Into Patient‐Level Exposure to Actionable Pharmacogenomic Medications in Australia Using a New National Pharmacogenomic Guideline. Clinical Pharmacology & Therapeutics. 2026;119(1):89-100. doi:10.1002/cpt.70006
BibTeX
@article{Ianni2026,
author = {Ianni, Bella D and Yiu, Chin Hang and Ali, Mohammad A and Lu, Christine Y},
title = {Insights Into Patient‐Level Exposure to Actionable Pharmacogenomic Medications in Australia Using a New National Pharmacogenomic Guideline},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
volume = {119},
number = {1},
pages = {89--100},
doi = {10.1002/cpt.70006}
}
EUVIMED